Mayo Clinic Laboratories’ updated focused pharmacogenomics panel uses real-time, PCR testing for targeted genotyping of 10 genes with known associations to medications used to treat a variety of disorders across a spectrum of specialities. In this “A Test in Focus” episode of the "Answers From the Lab" podcast, Ann Moyer, M.D., Ph.D., explains how this innovative assay helps guide providers on choosing the best treatment option for their patients.

“The goal of this panel would be that it should be useful for patients that are either on many different medications or patients where the differential diagnosis is still rather broad, where it's difficult to decide which medication to put the patient on,” Dr. Moyer says “Because these drugs metabolize so many different medications, hopefully this is a panel that, once the patient has it ordered, it can be reused again and again, throughout their care, no matter what specialty they're seeing.”

By including both genotype and phenotype evaluation of those genes with a high level of evidence for metabolic associations to medications, the test enables detailed insights on patients’ genetic dispositions, Dr. Moyer says. “We tried to be really careful and cognizant about making sure that we include all of the alleles that are relevant for various patient populations throughout the world. And I think that makes our tests something that should be useful for years to come.”

Listen to learn more about how our focused pharmacogenomics panel can help guide treatment selection and improve treatment outcomes for patients.

Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.

Testing

PGXQP | Focused Pharmacogenomics Panel, Varies

Useful information

• Preemptive or reactive genotyping of patients for pharmacogenomic purposes
• Providing an assessment for genes with strong drug-gene associations

Specimen requirements

Submit only 1 of the following specimens:

• Specimen Type: Whole blood
• Container/Tube: Lavender top (EDTA)
• Specimen Volume: 3 mL
• Collection Instructions:
  • Invert several times to mix blood.
  • Send specimen in original tube. Do not aliquot.
• Specimen Stability Information: Ambient (preferred) 9 days/Refrigerated 30 days

• Specimen Type: Saliva
• Patient Preparation: Patient should not eat, drink smoke, or chew gum 30 minutes prior to collection.
• Supplies: Saliva Swab Collection Kit (T786)
• Specimen Volume: 1 Swab
• Collection Instructions: Collect and send specimen per kit instructions.
• Additional Information: Due to lower concentration of DNA yielded from saliva, testing cannot proceed to reflex testing for 2D6 sequencing and will stop after initial testing is complete.
• Specimen Stability Information: Ambient 30 days

• Specimen Type: Extracted DNA
• Container/Tube: 2 mL screw top tube
• Specimen Volume: 100 mcL (microliters)
• Collection Instructions:
  • The preferred volume is 100 mcL at a concentration of 50 ng/mcL.
  • Include concentration and volume on tube.
• Specimen Stability Information: Frozen (preferred)/Ambient/Refrigerated

Performance information

• Analytic time: 3 to 14 days
• Day(s) and time(s) performed: Monday through Friday

The latest from Test in Focus

Unique Test Screens for Recently Identified Peripheral Neuropathy: Matthew Schultz, Ph.D., and Amy White, M.S., CGC

September 24, 2024

Matthew J. Schultz, Ph.D., and Amy L. White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related peripheral neuropathy is fairly common.

Panel Detects Demyelinating Neuropathy Biomarkers: John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S.

September 17, 2024

John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating autoimmune conditions.

Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D.

September 10, 2024

Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.

View MoreView Less